Komori
Pharma Foods International (2929) · FactAchieved

Increase in shares and capital through the exercise of stock acquisition rights

First written in FY2019-Q3. 10 of 12 entries say "Advanced", first in FY2019. Latest entry: FY2023.

12entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2019 – FY20232019: 220192020: 320202021: 320212022: 320222023: 12023
Same theme, other companies
Increase in shares, capital and other items through the exercise of stock optionsA theme 6 companies write about · 0 as a headwind · 5 as a tailwind

0 other companies' latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2023AchievedAnnual report

    「Common shares (Note) 1 29,073,800 5,200 - 29,079,000」

    The number of shares increased by 5,200 through the exercise of stock acquisition rights, and all remaining stock options were exercised.
  2. FY2023-Q1AdvancedAnnual report

    「1 August 2022–31 October 2022 (Note) 700 29,074,500 0 2,042 0 1,892 (Note) Increase resulting from the exercise of stock acquisition rights.」

    During the first quarter, the number of shares increased by 700 through the exercise of stock acquisition rights, bringing the total number of issued shares to 29,074,500.
  3. FY2022AdvancedAnnual report

    「1 August 2021–31 July 2022 (Note) 1 11,700 29,073,800 3 2,042 3 1,892」

    During the fiscal year, the number of shares increased by 11,700 through the exercise of stock acquisition rights, while stated capital and the capital reserve each increased by ¥3 million.
  4. FY2022-Q3AdvancedAnnual report

    「Note: The increase resulted from the exercise of stock acquisition rights.」

    The exercise of stock acquisition rights during the third quarter increased the number of issued shares, stated capital and the capital reserve.
  5. FY2022-Q1AdvancedAnnual report

    「1 August 2021–31 October 2021 (Note) 1,000 29,063,100 0 2,039 0 1,889 (Note) Increase resulting from the exercise of stock acquisition rights.」

    During the first quarter, the number of shares increased by 1,000 through the exercise of stock acquisition rights, bringing the number of issued shares to 29,063,100.
  6. FY2021AdvancedAnnual report

    「1 August 2020–31 July 2021 (Note) 1 18,700 29,062,100 5 2,038 5 1,889」

    During the fiscal year, the number of shares increased by 18,700 through the exercise of stock acquisition rights, while stated capital and the capital reserve each increased by ¥5 million.
  7. FY2021-Q2AdvancedAnnual report

    「1 November 2020–31 January 2021 (Note) 10,000 29,057,600 2,715 2,037,631 2,715 1,888,335 (Note) Increase resulting from the exercise of stock acquisition rights.」

    During the second quarter, the number of shares increased by 10,000 through the exercise of stock acquisition rights, while stated capital and the capital reserve each increased by ¥2,715 thousand.
  8. FY2021-Q1AdvancedAnnual report

    「1 August 2020–31 October 2020 (Note) 4,200 29,047,600 1,140 2,034,916 1,140 1,885,620 (Note) Increase resulting from the exercise of stock acquisition rights.」

    During the first quarter, the number of shares increased by 4,200 through the exercise of stock acquisition rights, while stated capital and the capital reserve each increased by ¥1,140 thousand.
  9. FY2020-Q3AdvancedAnnual report

    「1 February 2020–30 April 2020 (Note) 700 29,041,500 190 2,033,260 190 1,883,964 (Note) Increase resulting from the exercise of stock acquisition rights.」

    During the third quarter, the number of shares increased by 700 through the exercise of stock acquisition rights, while stated capital and the capital reserve each increased by ¥190 thousand.
  10. FY2020-Q2AdvancedAnnual report

    「1 November 2019–31 January 2020 (Note) 3,100 29,040,800 841 2,033,070 841 1,883,774 (Note) Increase resulting from the exercise of stock acquisition rights.」

    During the second quarter, the number of shares increased by 3,100 through the exercise of stock acquisition rights, while stated capital and the capital reserve each increased by ¥841 thousand.
  11. FY2019AdvancedAnnual report

    「Exercised 3,500 Unexercised balance 41,300」

    During the fiscal year, stock acquisition rights covering 3,500 shares were exercised, leaving 41,300 shares unexercised.
  12. FY2019-Q3First statedAnnual report

    「The increase resulted from the exercise of stock acquisition rights.」

    Between 1 February and 30 April 2019, the number of shares increased by 2,300 through the exercise of stock acquisition rights, while stated capital and the capital reserve each increased by ¥624 thousand.
Moved together

"Commercialization and Development Pipeline for New Functional Materials" moved the same way as this thread, in the same document, in 11 of its 12 moves.

1111101099★123456
  1. ★This thread
  2. 1Commercialization and Development Pipeline for New Functional Materials11×
  3. 2 적극ive efforts under the Foods with Function Claims system11×
  4. 3Development of antibody therapeutics using proprietary chicken antibody technology10×
  5. 4Raising Working Capital through Borrowings10×
  6. 5Advertising Investment and Product Brand Expansion in Mail-Order Sales9×
  7. 6Research and Development Expenditure9×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Pharma Foods International yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.